Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DTIC, CDDP, IFN-alpha, and IL-2 in Metastatic Melanoma
NCT00002669Phase 2Completed
- Sponsor
- European Organisation for Research and Treatment of Cancer
- Start
- Jun 1995
- Primary completion
- Aug 2002
- Modality
- Cytokines & Interferons, Small Molecules
- Countries
- 9
01
Overview
Phase 2, randomised, open-label trial of aldesleukin, interferon alfa, cisplatin and dacarbazine in melanoma (2 arms), sponsored by European Organisation for Research and Treatment of Cancer. Primary endpoint: Rate of disease stabilization up to 6 months. Started Jun 1995; status: completed.
02
Drugs
aldesleukininterferon alfacisplatindacarbazine
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT00002669.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00002669.